<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00212589</url>
  </required_header>
  <id_info>
    <org_study_id>11.02</org_study_id>
    <nct_id>NCT00212589</nct_id>
  </id_info>
  <brief_title>Patients Preference for Oral or i.v. Therapy</brief_title>
  <official_title>A Randomized Crossover Trial Comparing Oral Capecitabine and Intravenous Fluorouracil + Folinic Acid (Nordic FU/FA Regimen) for Patient Preference in Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <brief_summary>
    <textblock>
      Until recently, bolus 5-flourouracil (FU) + folinic acid (FA) has been considered the
      standard chemotherapy for patients with colorectal cancer. Several studies have shown that
      Capecitabine is as effective as Mayo regimen. The Nordic FU/FA schedule was developed to be
      an active and tolerable bolus regimen. The Nordic regimen consists of a short (3 minutes)
      bolus injection of FU and 30 minutes later FA for 2 consecutive days each 2 weeks. In
      randomized studies efficacy is comparable to other FU/FA regimens.

      It is claimed that patients prefer oral therapy and in a randomized study comparing oral
      therapy (UFT/FA) and bolus FU/FA (Mayo) 84% preferred oral therapy.

      In the present randomized cross-over study patients were randomized for 3 courses of Nordic
      FU/FA followed by 2 courses of Capecitabine (or vice versa), and patients were asked for
      their preference.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date>April 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil + folinic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for treatment with a FU-regime

          -  WHO Performance Status 0-1

          -  Life expectancy &gt; 3 months

          -  Adequate haematological, renal and hepatic functions

          -  Adequate contraceptives

          -  Written informed consent

        Exclusion Criteria:

          -  Known CNS-metastases

          -  Prior treatment with chemotherapy

          -  Pregnant or breast feeding women

          -  Current infection, unresolved bowel obstruction or subobstruction, uncontrolled
             Crohn's disease or ulcerative colitis

          -  other serious illness or medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Pfeiffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, Odense University Hospital, DK-5000 Odense C, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Esbjerg Hospital</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Sonderborg Hospital</name>
      <address>
        <city>Sonderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Lima AP, del Giglio A. Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. Eur J Cancer Care (Engl). 2005 May;14(2):151-4.</citation>
    <PMID>15842464</PMID>
  </reference>
  <reference>
    <citation>Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002 Feb;38(3):349-58.</citation>
    <PMID>11818199</PMID>
  </reference>
  <verification_date>May 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>September 13, 2005</last_update_submitted>
  <last_update_submitted_qc>September 13, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2005</last_update_posted>
  <keyword>Patients preference</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Fluorouracil + folinic acid</keyword>
  <keyword>Cross-over study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

